

Kimmo Porkka

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9150279/publications.pdf>

Version: 2024-02-01

107
papers

5,768
citations

126907

33
h-index

82547

72
g-index

111
all docs

111
docs citations

111
times ranked

7692
citing authors

#	ARTICLE	IF	CITATIONS
1	Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2022, 12, 388-401.	9.4	73
2	Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status. <i>Blood</i> , 2022, 139, 2145-2155.	1.4	38
3	Targeting Apoptosis Pathways With BCL2 and MDM2 Inhibitors in Adult B-cell Acute Lymphoblastic Leukemia. <i>HemaSphere</i> , 2022, 6, e701.	2.7	4
4	Incidence of myelodysplastic syndromes in Finland 1997–2016. <i>Leukemia Research</i> , 2022, 116, 106839.	0.8	5
5	Copy number alterations define outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Haematologica</i> , 2022, , .	3.5	1
6	International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. <i>Blood</i> , 2022, 140, 1200-1228.	1.4	814
7	RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses. <i>Leukemia</i> , 2021, 35, 1087-1099.	7.2	32
8	Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial. <i>Blood Advances</i> , 2021, 5, 1110-1121.	5.2	33
9	Patient-tailored design for selective co-inhibition of leukemic cell subpopulations. <i>Science Advances</i> , 2021, 7, .	10.3	28
10	The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study. <i>Leukemia and Lymphoma</i> , 2021, 62, 2040-2043.	1.3	7
11	Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia. <i>Npj Precision Oncology</i> , 2021, 5, 71.	5.4	12
12	Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial. <i>HemaSphere</i> , 2021, 5, e617.	2.7	10
13	Genome-wide association study identifies susceptibility loci for acute myeloid leukemia. <i>Nature Communications</i> , 2021, 12, 6233.	12.8	17
14	Preliminary Results from a Phase Ib Study Exploring MDM2 Inhibitor Siremadlin (HDM201) in Combination with B-Cell Lymphoma-2 (BCL-2) Inhibitor Venetoclax in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (HR-MDS). <i>Blood</i> , 2021, 138, 1283-1283.	1.4	3
15	Ex Vivo Drug Sensitivity Testing to Predict Response to Venetoclax + Azacitidine in Acute Myeloid Leukemia: Interim Results of the Prospective Multicenter Phase II Venex Trial. <i>Blood</i> , 2021, 138, 228-228.	1.4	1
16	Allogeneic Hematopoietic Cell Transplantation Outcomes of Patients with R/R AML or Higher-Risk MDS Treated with the TIM-3 Inhibitor MBG453 (Sabatolimab) and Hypomethylating Agents. <i>Blood</i> , 2021, 138, 3677-3677.	1.4	5
17	Multi-parametric single cell evaluation defines distinct drug responses in healthy hematologic cells that are retained in corresponding malignant cell types. <i>Haematologica</i> , 2020, 105, 1527-1538.	3.5	19
18	KIT pathway upregulation predicts dasatinib efficacy in acute myeloid leukemia. <i>Leukemia</i> , 2020, 34, 2780-2784.	7.2	6

#	ARTICLE	IF	CITATIONS
19	Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets. <i>Leukemia</i> , 2020, 35, 1964-1975.	7.2	35
20	Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission. <i>New England Journal of Medicine</i> , 2020, 383, 2526-2537.	27.0	265
21	Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma. <i>Investigational New Drugs</i> , 2020, 38, 1448-1453.	2.6	58
22	Pan-RAF inhibition induces apoptosis in acute myeloid leukemia cells and synergizes with BCL2 inhibition. <i>Leukemia</i> , 2020, 34, 3186-3196.	7.2	22
23	EHA evaluation of the ESMOâ€”Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies. <i>ESMO Open</i> , 2020, 5, e000611.	4.5	10
24	Immune profiles in acute myeloid leukemia bone marrow associate with patient age, T-cell receptor clonality, and survival. <i>Blood Advances</i> , 2020, 4, 274-286.	5.2	38
25	Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia. <i>Blood Advances</i> , 2020, 4, 546-559.	5.2	36
26	Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia. <i>Haematologica</i> , 2020, 105, 708-720.	3.5	99
27	Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study. <i>Blood</i> , 2020, 136, 1-2.	1.4	54
28	CC-486 Prolongs Survival for Patients with Acute Myeloid Leukemia (AML) in Remission after Intensive Chemotherapy (IC) Independent of the Presence of Measurable Residual Disease (MRD) at Study Entry: Results from the QUAZAR AML-001 Maintenance Trial. <i>Blood</i> , 2020, 136, 32-33.	1.4	12
29	Escalated dosing schedules of CC-486 for patients experiencing first acute myeloid leukemia (AML) relapse: Results from the phase III QUAZAR AML-001 maintenance trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 7513-7513.	1.6	2
30	Sabatolimab (MBG453) Dose Selection and Dose-Response Analysis in Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML): Population Pharmacokinetics (PK) Modeling and Evaluation of Clinical Efficacy/Safety By Dose. <i>Blood</i> , 2020, 136, 40-42.	1.4	7
31	Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia. <i>Blood</i> , 2019, 134, 1132-1143.	1.4	81
32	Elevated expression of S100A8 and S100A9 correlates with resistance to the BCL-2 inhibitor venetoclax in AML. <i>Leukemia</i> , 2019, 33, 2548-2553.	7.2	25
33	Acute Lymphoblastic Leukemia With INPP5D-ABL1 Fusion Responds to Imatinib Treatment. <i>Journal of Pediatric Hematology/Oncology</i> , 2019, 41, e481-e483.	0.6	2
34	ERCC6L2 defines a novel entity within inherited acute myeloid leukemia. <i>Blood</i> , 2019, 133, 2724-2728.	1.4	35
35	Hemap: An Interactive Online Resource for Characterizing Molecular Phenotypes across Hematologic Malignancies. <i>Cancer Research</i> , 2019, 79, 2466-2479.	0.9	23
36	Dasatinib and navitoclax act synergistically to target NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia. <i>Leukemia</i> , 2019, 33, 1360-1372.	7.2	40

#	ARTICLE	IF	CITATIONS
37	Immune cell constitution in bone marrow microenvironment predicts outcome in adult ALL. <i>Leukemia</i> , 2019, 33, 1570-1582.	7.2	43
38	Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). <i>Blood</i> , 2019, 134, 570-570.	1.4	64
39	Case studies investigating genetic heterogeneity between anatomically distinct bone marrow compartments in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 3002-3005.	1.3	0
40	Germline alterations in a consecutive series of acute myeloid leukemia. <i>Leukemia</i> , 2018, 32, 2282-2285.	7.2	24
41	Chimeric NUP98â€“NSD1 transcripts from the cryptic t(5;11)(q35.2;p15.4) in adult de novo acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 725-732.	1.3	5
42	Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML. <i>Leukemia</i> , 2018, 32, 1643-1656.	7.2	75
43	RUNX1 Mutations Identify an Entity of Blast Phase Chronic Myeloid Leukemia (BP-CML) Patients with Distinct Phenotype, Transcriptional Profile and Drug Vulnerabilities. <i>Blood</i> , 2018, 132, 4257-4257.	1.4	6
44	Multi-Parametric Single Cell Profiling Defines Distinct Drug Responses in Healthy Hematological Cell Lineages That Are Retained in Corresponding Malignant Cell Types. <i>Blood</i> , 2018, 132, 264-264.	1.4	5
45	Paradox-Breaker Pan-RAF Inhibitors Induce an AML-Specific Cytotoxic Response and Synergize with Venetoclax to Display Superior Antileukemic Activity. <i>Blood</i> , 2018, 132, 2210-2210.	1.4	2
46	Predictive Response Biomarkers for BET Inhibitors in AML. <i>Blood</i> , 2018, 132, 2749-2749.	1.4	2
47	Dasatinib Changes Immune Cell Profiles Concomitant with Reduced Tumor Growth in Several Murine Solid Tumor Models. <i>Cancer Immunology Research</i> , 2017, 5, 157-169.	3.4	36
48	Low interleukin-2 concentration favors generation of early memory T cells over effector phenotypes during chimeric antigen receptor T-cell expansion. <i>Cytotherapy</i> , 2017, 19, 689-702.	0.7	80
49	Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia. <i>Journal of Clinical Oncology</i> , 2017, 35, 175-184.	1.6	36
50	JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cellâ€“induced protection of AML. <i>Blood</i> , 2017, 130, 789-802.	1.4	90
51	Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib. <i>Haematologica</i> , 2017, 102, 1361-1367.	3.5	28
52	Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia. <i>PLoS ONE</i> , 2017, 12, e0171041.	2.5	7
53	Identification and Clinical Exploration of Individualized Targeted Therapeutic Approaches in Acute Myeloid Leukemia Patients By Integrating Drug Response and Deep Molecular Profiles. <i>Blood</i> , 2017, 130, 854-854.	1.4	1
54	Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors. <i>Oncotarget</i> , 2017, 8, 22606-22615.	1.8	13

#	ARTICLE	IF	CITATIONS
55	Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testing. <i>Oncotarget</i> , 2017, 8, 56338-56350.	1.8	35
56	Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia. <i>Future Oncology</i> , 2016, 12, 293-302.	2.4	36
57	IL1RAP antibodies block IL-1-induced expansion of candidate CML stem cells and mediate cell killing in xenograft models. <i>Blood</i> , 2016, 128, 2683-2693.	1.4	77
58	Leukemic Stem Cell Quantification in Newly Diagnosed Patients With Chronic Myeloid Leukemia Predicts Response to Nilotinib Therapy. <i>Clinical Cancer Research</i> , 2016, 22, 4030-4038.	7.0	20
59	Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity. <i>Cancer</i> , 2016, 122, 1398-1407.	4.1	47
60	Enrichment of rare variants in population isolates: single AICDA mutation responsible for hyper-IgM syndrome type 2 in Finland. <i>European Journal of Human Genetics</i> , 2016, 24, 1473-1478.	2.8	22
61	Assessment of bone marrow lymphocytic status during tyrosine kinase inhibitor therapy and its relation to therapy response in chronic myeloid leukaemia. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1041-1050.	2.5	24
62	A Novel Homozygous CTC1 Germline Mutation Associated with Bone Marrow Failure. <i>Blood</i> , 2016, 128, 1508-1508.	1.4	2
63	No Differences in Molecular Relapse-Free Survival after Stopping Imatinib Treatment of Chronic Myeloid Leukemia Between Patients with Prior 4.5 Log Reduction (MR4.5) but Detectable and Patients with Undetectable Disease in the EURO-SKI Trial. <i>Blood</i> , 2016, 128, 789-789.	1.4	9
64	Intrinsic resistance to PIM kinase inhibition in AML through p38-mediated feedback activation of mTOR signaling. <i>Oncotarget</i> , 2016, 7, 37407-37419.	1.8	16
65	Identification of Optimized Compound Combinations for the Treatment of NUP98-NSD1+ AML. <i>Blood</i> , 2016, 128, 4711-4711.	1.4	0
66	Autoimmunity, hypogammaglobulinemia, lymphoproliferation, and mycobacterial disease in patients with activating mutations in STAT3. <i>Blood</i> , 2015, 125, 639-648.	1.4	229
67	Somatic MED12 mutations are associated with poor prognosis markers in chronic lymphocytic leukemia. <i>Oncotarget</i> , 2015, 6, 1884-1888.	1.8	49
68	Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation. <i>Nature</i> , 2015, 519, 102-105.	27.8	207
69	The analysis of clonal diversity and therapy responses using STAT3 mutations as a molecular marker in large granular lymphocytic leukemia. <i>Haematologica</i> , 2015, 100, 91-99.	3.5	88
70	Enlarged Memory T-Cell Pool and Enhanced Th1-Type Responses in Chronic Myeloid Leukemia Patients Who Have Successfully Discontinued IFN- γ Monotherapy. <i>PLoS ONE</i> , 2014, 9, e87794.	2.5	41
71	Chronic myeloid leukemia patients' adherence to peroral tyrosine kinase inhibitors compared with adherence as estimated by their physicians. <i>Patient Preference and Adherence</i> , 2014, 8, 1619.	1.8	41
72	Dasatinib promotes Th1-type responses in granzyme B expressing T-cells. <i>Oncolmmunology</i> , 2014, 3, e28925.	4.6	38

#	ARTICLE	IF	CITATIONS
73	Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. <i>Scientific Reports</i> , 2014, 4, 5193.	3.3	243
74	Reduced Expression of CD62L Is Associated with Increased ADAM17 Activity and Predicts Molecular Response to Nilotinib Therapy in Patients with Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP). <i>Blood</i> , 2014, 124, 4522-4522.	1.4	1
75	Early Disease Relapse after Tyrosine Kinase Inhibitor Treatment Discontinuation in CML Is Related Both to Low Number and Impaired Function of NK-Cells. <i>Blood</i> , 2014, 124, 812-812.	1.4	33
76	An open-label, phase 1b, dose-escalation study (CA180-373) of dasatinib plus nivolumab, an investigational anti-programmed cell death 1 (PD-1) antibody, in patients (pts) with previously treated chronic myeloid leukemia (CML).. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS7119-TPS7119.	1.6	2
77	Stroma-Derived Factors Significantly Impact the Drug Response Profiles of Patient-Derived Primary AML Cells: Implications for Drug Sensitivity Testing. <i>Blood</i> , 2014, 124, 3505-3505.	1.4	0
78	The Use of RNA Sequencing to Identify Disease-Specific Gene Expression Signatures and Critical Regulatory Networks Across Hematologic Malignancies. <i>Blood</i> , 2014, 124, 2203-2203.	1.4	3
79	Integration of Ex Vivo Drug Testing and in-Depth Molecular Profiling Reveals Oncogenic Signaling Pathways and Novel Therapeutic Strategies for Multiple Myeloma. <i>Blood</i> , 2014, 124, 2046-2046.	1.4	3
80	Dasatinib-Induced Reduction of Tumor Growth Is Accompanied By the Changes in the Immune Profile in a Melanoma B16.OVA Mouse Model. <i>Blood</i> , 2014, 124, 1408-1408.	1.4	0
81	Landscape of Driver Lesions in Multiple Myeloma and Consequences for Targeted Drug Response. <i>Blood</i> , 2014, 124, 3351-3351.	1.4	0
82	Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2013, 3, 1416-1429.	9.4	334
83	Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. <i>Blood</i> , 2013, 121, 4541-4550.	1.4	252
84	Novel Activating STAT5B Mutations As Drivers Of T-ALL. <i>Blood</i> , 2013, 122, 3863-3863.	1.4	5
85	High-Throughput Drug Sensitivity and Resistance Testing (DSRT) Platform Reveals Novel Candidate Drugs For Advanced Phase BCR-ABL1-Positive Leukemia. <i>Blood</i> , 2013, 122, 2719-2719.	1.4	0
86	Somatic STAT3 Mutations in Large Granular Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2012, 366, 1905-1913.	27.0	681
87	Bosutinib As Therapy for Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib: 36-Month Minimum Follow-up Update. <i>Blood</i> , 2012, 120, 3779-3779.	1.4	2
88	Bosutinib Safety Profile and Management of Toxicities in Leukemia Patients with Resistance or Intolerance to Imatinib and Other Tyrosine Kinase Inhibitors. <i>Blood</i> , 2011, 118, 2760-2760.	1.4	2
89	Development of a Cancer Pharmacopeia-Wide Ex-Vivo Drug Sensitivity and Resistance Testing (DSRT) Platform: Identification of MEK and mTOR As Patient-Specific Molecular Drivers of Adult AML and Potent Therapeutic Combinations with Dasatinib. <i>Blood</i> , 2011, 118, 2487-2487.	1.4	0
90	Tyrosine Kinase Inhibitor Therapy Induced Changes in Humoral Immunity in Patients with Chronic Myeloid Leukemia. <i>Blood</i> , 2011, 118, 1699-1699.	1.4	4

#	ARTICLE	IF	CITATIONS
91	Recurrent Missense Mutations in the STAT3 Gene in LGL Leukemia Provide Insights to Pathogenetic Mechanisms and Suggest Potential Diagnostic and Therapeutic Applications. <i>Blood</i> , 2011, 118, 936-936.	1.4	6
92	Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. <i>Blood</i> , 2010, 116, 772-782.	1.4	168
93	Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. <i>Cancer</i> , 2010, 116, 377-386.	4.1	134
94	Suboptimal responses in chronic myeloid leukemia: milestones and mechanisms. <i>Expert Review of Hematology</i> , 2009, 2, 81-91.	2.2	3
95	A Randomized Phase II Study Comparing Imatinib and the Combination of Imatinib and Pegylated Interferon Alpha-2b in Newly Diagnosed Non-High Risk Chronic Myeloid Leukemia (CML) Patients in Complete Hematological Remission After Imatinib Induction Therapy.. <i>Blood</i> , 2009, 114, 3280-3280.	1.4	2
96	The European Treatment and Outcome Study (EUTOS) for Chronic Myeloid Leukemia (CML). A Prospective, Population-Based European Registry.. <i>Blood</i> , 2009, 114, 4272-4272.	1.4	11
97	Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosomeâ€“positive leukemia. <i>Blood</i> , 2008, 112, 1005-1012.	1.4	366
98	Cytogenetic and Molecular Response to Imatinib in High Risk (Sokal) Chronic Myeloid Leukemia (CML): Results of An European Leukemianet Prospective Study Comparing 400 Mg and 800 Mg Front-Line. <i>Blood</i> , 2008, 112, 185-185.	1.4	13
99	Imatinib Discontinuation Following a Major Molecular Response: Impact of Interferon Alpha and Leukemia Stem Cell Burden (The STOP Study).. <i>Blood</i> , 2008, 112, 2121-2121.	1.4	4
100	Dasatinib 100 Mg Once Daily (QD) Maintains Long-Term Efficacy and Minimizes the Occurrence of Pleural Effusion: An Analysis of 24-Month Data in Patients with Resistance, Suboptimal Response, or Intolerance to Imatinib (CA180-034).. <i>Blood</i> , 2008, 112, 3242-3242.	1.4	5
101	Clonal Expansion of T/NK-Cells during Tyrosine Kinase Inhibitor Dasatinib Therapy. <i>Blood</i> , 2008, 112, 573-573.	1.4	3
102	A Prospective Study of Imatinib 400 mg vs 800 mg Frontline in High Risk Ph+ Chronic Myeloid Leukemia (CML) Patients.. <i>Blood</i> , 2007, 110, 26-26.	1.4	4
103	Clonal Large Granular Lymphocyte (LGL) Expansion Associated with Dasatinib Therapy.. <i>Blood</i> , 2007, 110, 2938-2938.	1.4	4
104	Nordic CML Study Group Quality and Standardization Rounds for Quantitative RT-PCR of BCR-ABL To Facilitate Reporting on the International Scale.. <i>Blood</i> , 2007, 110, 4559-4559.	1.4	1
105	Acquired Extramedullary Resistance to Dasatinib Due to Selection of Philadelphia-Positive Lymphoblast Clone Harboring a T315I BCR-ABL Gene Mutation: Reversal by Dose Escalation and Hydroxyurea.. <i>Blood</i> , 2005, 106, 4579-4579.	1.4	0
106	Novel DNA Copy Number Changes in Hematological Malignancies: A cDNA-Based CGH Microarray Screening of CML, AML and CLL Cases without Chromosomal Imbalances in G-Banding.. <i>Blood</i> , 2004, 104, 4418-4418.	1.4	0
107	Efficacy of conventionalâ€“dose cytarabine, idarubicin and thioguanine (IAT) versus intermediateâ€“dose cytarabine and idarubicin (IdAraCâ€“da) in the induction treatment of AML: longâ€“term results of the prospective randomized nationwide AMLâ€“2003 study by the Finnish Leukemia Group. <i>European Journal of Haematology</i> , 0, . . .	2.2	1